Top Markets
Coin of the day
9 Meters Biopharma, Inc. 9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.

NMTR
주식 순위 #40885
Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a... Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.
주가
$0.0169
마지막 동기화: 2023-08-21
시가총액
$66.40K
변동 (1일)
4.32%
변동 (1년)
0.00%
국가
US
거래 9 Meters Biopharma, Inc. (NMTR)

카테고리

9 Meters Biopharma, Inc. (NMTR)의 매출
Aug 2026 기준 매출 TTM: 0
9 Meters Biopharma, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
9 Meters Biopharma, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE